Your browser doesn't support javascript.
loading
APE-Gen2.0: Expanding Rapid Class I Peptide-Major Histocompatibility Complex Modeling to Post-Translational Modifications and Noncanonical Peptide Geometries.
Fasoulis, Romanos; Rigo, Mauricio M; Lizée, Gregory; Antunes, Dinler A; Kavraki, Lydia E.
Afiliação
  • Fasoulis R; Department of Computer Science, Rice University, Houston, Texas 77005, United States.
  • Rigo MM; Department of Computer Science, Rice University, Houston, Texas 77005, United States.
  • Lizée G; Department of Melanoma Medical Oncology─Research, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States.
  • Antunes DA; Department of Biology and Biochemistry, University of Houston, Houston, Texas 77004, United States.
  • Kavraki LE; Department of Computer Science, Rice University, Houston, Texas 77005, United States.
J Chem Inf Model ; 64(5): 1730-1750, 2024 03 11.
Article em En | MEDLINE | ID: mdl-38415656
ABSTRACT
The recognition of peptides bound to class I major histocompatibility complex (MHC-I) receptors by T-cell receptors (TCRs) is a determinant of triggering the adaptive immune response. While the exact molecular features that drive the TCR recognition are still unknown, studies have suggested that the geometry of the joint peptide-MHC (pMHC) structure plays an important role. As such, there is a definite need for methods and tools that accurately predict the structure of the peptide bound to the MHC-I receptor. In the past few years, many pMHC structural modeling tools have emerged that provide high-quality modeled structures in the general case. However, there are numerous instances of non-canonical cases in the immunopeptidome that the majority of pMHC modeling tools do not attend to, most notably, peptides that exhibit non-standard amino acids and post-translational modifications (PTMs) or peptides that assume non-canonical geometries in the MHC binding cleft. Such chemical and structural properties have been shown to be present in neoantigens; therefore, accurate structural modeling of these instances can be vital for cancer immunotherapy. To this end, we have developed APE-Gen2.0, a tool that improves upon its predecessor and other pMHC modeling tools, both in terms of modeling accuracy and the available modeling range of non-canonical peptide cases. Some of the improvements include (i) the ability to model peptides that have different types of PTMs such as phosphorylation, nitration, and citrullination; (ii) a new and improved anchor identification routine in order to identify and model peptides that exhibit a non-canonical anchor conformation; and (iii) a web server that provides a platform for easy and accessible pMHC modeling. We further show that structures predicted by APE-Gen2.0 can be used to assess the effects that PTMs have in binding affinity in a more accurate manner than just using solely the sequence of the peptide. APE-Gen2.0 is freely available at https//apegen.kavrakilab.org.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Hominidae Limite: Animals Idioma: En Revista: J Chem Inf Model Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Hominidae Limite: Animals Idioma: En Revista: J Chem Inf Model Ano de publicação: 2024 Tipo de documento: Article